mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
“Consistent with this, the NMDA receptor antagonist ketamine acutely activates mTORC1 signaling in mouse neurons, which coincides with an increased translation of synaptic proteins (Li et al., 2010).”
BackgroundAKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
mTOR at the nexus of nutrition, growth, ageing and disease
Liu, G. Y., & Sabatini, D. M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0199-y · Cited by 2,737
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.035 · Cited by 2,070
“Consistent with this, the NMDA receptor antagonist ketamine acutely activates mTORC1 signaling in mouse neurons, which coincides with an increased translation of synaptic proteins (Li et al., 2010).”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
“Recent evidence indicates that cortical mTOR signalling underlies ketamine-mediated antidepressant response”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
A standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581
“It should be noted that some behavioral measures, such as learned helplessness and novelty-suppressed feeding, address some of these validities and are useful models in studying aspects of depression-like behavio”
Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex
McEwen, B. S., Nasca, C., & Gray, J. D. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.171 · Cited by 1,574
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“378,379 Keta-mine may induce the activation of mTOR by the upstream kinase Akt, regulate the phosphorylation of GSK-3 β , and exert anti-depressant effects.”
BackgroundPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
“We specifically designed these experiments to mimic previous studies of ketamine (Li et al., 2010) so that we might directly compare these two compounds, and, to a first approximation, they appear to be remarkably similar.”
BackgroundMethodInfluentialMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
“One study found decreased T reg percentage in association with reduced IL-10 and TGF-beta in depressed patients versus controls (Li et al., 2010b), and a second study reported that antidepressant treatment led to increased CD4+CD25+ T reg percentage, which was associated with decreased IL-1-beta…”
BackgroundResultRapid regulation of depression-related behaviours by control of midbrain dopamine neurons
Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M., Koo, J. W., Ferguson, D., Tsai, H.-C., Pomeranz, L., Christoffel, D. J., et al. (2013) · Nature · doi:10.1038/nature11713 · Cited by 1,156
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
“The requirement for mTOR signaling is consistent with our recent findings that ketamine directly activates several components of the mTOR pathway (25).”
InfluentialSelf-citationTowards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
“…sustained effects in rodent models similar to those seen in depressed patients (Autry et al., 2011; Du et al., 2006; Koike et al., 2011; Li et al., 2010, 2011; Maeng et al., 2008; Yilmaz et al., 2002), others have failed to demonstrate the enduring effects of an acute ketamine dosing…”
BackgroundResultInfluentialKetamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
“The increase in synapse number and function is accompanied by increased levels of synaptic proteins, including GluA1 in the PFC (Li et al., 2010; Li et al., 2011; Maeng et al., 2008).”
BackgroundInfluentialSelf-citationPanwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
“192 The mTORC1-mediated autophagy was found to be strongly correlated with the pathogenesis of neurodegenerative disorders like Alzheimer ’ s disease (AD), and Parkinson ’ s disease (PD).”
BackgroundThe chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
“Within 24 h, a single ketamine injection also reversed the loss of synaptic proteins and atrophy of dendritic spines in the PFC and the associated electrophysiological deficits (Li et al., 2010, 2011b; Duman et al., 2012; Tang et al., 2015a).”
BackgroundInfluentialBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“…downstream effects of ketamine Several intracellular signaling pathways, in addition to eEF2 kinase signaling, such as mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3 (GSK-3) have been implicated in the antidepressant effects of ketamine (Beurel et al., 2011; Li et al., 2010).”
BackgroundZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808
Self-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
“While the riluzole for relapse prevention strategy was based on potential synergy between ketamine and riluzole involving modulation of glutamate signaling, the recent identification of additional signaling pathways implicated in the antidepressant action of ketamine suggests new targets for synergy (7, 29-31).”
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 775
“Furthermore, by antagonizing the glutamatergic NMDA receptor, ketamine was found to accelerate the release of presynaptic glutamate, thereby enhancing the regional activity of the excitatory network, and eventually leading to a significant change in synaptic plasticity and connectivity [108, 109].”
BackgroundBDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Self-citationLipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Self-citationStructure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Integrating neuroimmune systems in the neurobiology of depression
Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.69 · Cited by 668
Self-citationSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
“Increasing evidence suggests that signaling pathways (4–6) may converge to increase spine density in prefrontal cortical pyramidal cells (4, 7, 8), potentially accelerating remission by directly and selectively reversing prefrontal cortical synapse loss, a putative neurobiological substrate of depression that occurs i…”
BackgroundPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Gene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications
Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622
“This interaction could also exert effects on the mammalian target of rapamycin pathway, a pathway that is activated by Akt and has been implicated in the antidepressant activity of ketamine (Li et al, 2010; Markman et al, 2010).”
BackgroundHow do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Self-citationFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“…research is evaluating the pharmacological and intracellular effects that are responsible for the antidepressant effects of ketamine (e.g. Li et al., 2010; Autry et al., 2011), which will aid the development of novel glutamatergic drugs (for an excellent review on the preclinical…”
BackgroundKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
“Glucocorticoids released in response to stress have also been shown to negatively regulate mTOR activity (Polman et al., 2012) and mTOR-dependent synapse formation, which is thought to underlie the rapid antidepressant effects of ketamine (Li et al., 2010, Li et al., 2011).”
BackgroundSchwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
“In support of this hypothesis, it was shown that blocking mTOR with an infusion of rapamycin, an mTOR inhibitor, in the cortex blocked ketamine’s antidepressant-like effects and synaptogenesis (129).”
General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis
Brown, E. N., Purdon, P. L., & Van Dort, C. J. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153200 · Cited by 539
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
“The results demonstrate that rapamycin pretreatment completely blocks the induction of spine formation by ketamine, as well as the induction of 5-HT and hypocretin-induced EPSCs (Li et al., 2010).”
InfluentialSelf-citationAnimal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
“A clinically validated example of one such a rapidly acting agent is ketamine (aan het Rot et al. 2010), and recent preclinical experiments reveal that ketamine’s antidepressant effects may be mediated through rapid forms of glutamatergic synaptic plasticity (Li et al. 2010).”
BackgroundEdaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 520
“Furthermore, some striking studies have found that ketamine can produce rapid antidepressant effects, and its s-isomer, esketamine has been approved by the Food and Drug Administration (FDA) to treat adults with treatment-resistant depression [5, 6].”
BackgroundSelf-citationAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Ketamine for chronic pain: risks and benefits
Niesters, M., Martini, C., & Dahan, A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12094 · Cited by 508
“the NMDAR, activates the mTOR (mammalian target of rapamycin) pathway increasing the expression of synaptic proteins and the density of dendritic spines, and causing an antidepressant response within one day.[49] Many chronic pain patients cope with”
BackgroundWang, M., Yang, Y., Wang, C.-J., Gamo, N. J., Jin, L. E., Mazer, J. A., Morrison, J. H., Wang, X.-J., & Arnsten, A. F. T. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.032 · Cited by 489
“Rodent models suggest that these beneficial actions of ketamine may occur via increased AMPA-mTOR signaling, leading to increased spines in medial PFC (Li et al., 2010).”
BackgroundLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Kraus, C., Castrén, E., Kasper, S., & Lanzenberger, R. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.007 · Cited by 471
“Thereby especially new treatment forms in the glutamatergic system such as NMDA-receptor antagonist ketamine would be of special interest, since ketamine leads to increased synaptic plasticity by enhancing number and function of spine synapses (Li et al., 2010).”
BackgroundLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
“Ketamine antagonizes NMDA receptors on GABAergic interneurons and on postsynaptic neurons; the former disinhibits cortical glutamatergic neurons (83) and the latter increases synthesis of intracellular growth factors, such as brain-derived neurotrophic factor (81,82).”
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Ketamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455
Self-citationDendritic Spines in Depression: What We Learned from Animal Models
Qiao, H., Li, M.-X., Xu, C., Chen, H.-B., An, S.-C., & Ma, X.-M. (2016) · Neural Plasticity · doi:10.1155/2016/8056370 · Cited by 446
“The rapid antidepressant-like properties of ketamine, an NMDA receptor antagonist, result from increased synaptic signaling proteins and increased number and function of new spine synapses via activating the mammalian target of rapamycin (mTOR) pathway in the rat mPFC and hippocampus [295–298].”
BackgroundStuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
“An intriguing subject for future research is the investigation of the procognitive correlates of the ketamine-induced enhanced prefrontal plasticity demonstrated in rodents and supported by clinical studies (56, 73, 74).”
BackgroundSelf-citationKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
“Synaptogenesis in response to mTOR activation is hypothesized to contribute to ketamine's acute and sustained antidepressant effects (54).”
BackgroundKim, T., Vidal, G. S., Djurisic, M., William, C. M., Birnbaum, M. E., Garcia, K. C., Hyman, B. T., & Shatz, C. J. (2013) · Science · doi:10.1126/science.1242077 · Cited by 410
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
“Once stimulation of AMPA receptors is restored, antidepressant effects are mediated by stimulation of signaling in the Akt/mammalian target of rapamycin pathway, resulting in a rapid sprouting of dendritic spines (87).”
BackgroundResultSelf-citationLiu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
“A two factor (ketamine × time) mixed-design ANOVA conducted on the FST data from each genotype.”
InfluentialSelf-citationNeural basis of major depressive disorder: Beyond monoamine hypothesis
Boku, S., Nakagawa, S., Toda, H., & Hishimoto, A. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12604 · Cited by 402
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Self-citationZhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
“[14] have reported that the activation of mTOR in prefrontal cortex underlies the antidepressant effects of ketamine in rats.”
BackgroundSelf-citationThe mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder
Jernigan, C. S., Goswami, D. B., Austin, M. C., Iyo, A. H., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.05.010 · Cited by 386
“…that the fast antidepressant response to NMDA receptor antagonists (ketamine and Ro 25-6981) is mediated by rapid activation of the mTOR pathway leading to an increase in synaptic signaling proteins and increased number and function of new spine synapses in the PFC of rats (Li et al., 2010).”
InfluentialRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“Hence, further research exploring downstream mechanisms such as reported changes in synaptogenesis via mammalian target of rapamycin (Li et al , 2010), enhanced synaptic efficacy via inhibition of eukaryotic elongation factor (eEF2) kinase, dephophorylation of eEF2, and augmentation of BDNF…”
Neural control of chronic stress adaptation
Herman, J. P. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00061 · Cited by 384
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
“The antidepressant actions of ketamine are blocked by pretreatment with a glutamate-AMPA receptor antagonist (Maeng et al., 2008; Li et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationmTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Hare, B. D., & Duman, R. S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0685-9 · Cited by 366
“Also consistent with the synaptic effects of ketamine [19, 20, 22], this photostimulation paradigm significantly increased the number and function of spine-synapses in the mPFC, demonstrating structural as well as behavioral consequences.”
BackgroundSelf-citationDuman, R. S., & Li, N. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0357 · Cited by 362
Self-citationMiller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
“Ketamine evokes a rapid increase in protein synthesis and enhances excitatory synaptic transmission in cortical neurons (Li et al., 2010; Autry et al., 2011).”
BackgroundMethodResultInfluentialMoriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Plitman, E., Sano, Y., Tarumi, R., ElSalhy, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0252-9 · Cited by 357
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
“Consistent with a critical role of mTOR in preventing depressive states, studies indicate that activation of the mTORC1 pathway is required for the rapid antidepressant activity of NMDA receptor antagonists such as ketamine and Ro 25– 6981, a specific blocker of NR2B-containing NMDA receptors (160, 161).”
BackgroundHigh-Fat Diet Induced Anxiety and Anhedonia: Impact on Brain Homeostasis and Inflammation
Dutheil, S., Ota, K. T., Wohleb, E. S., Rasmussen, K., & Duman, R. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.357 · Cited by 355
“All rights reserved 0893-133X/16 www.neuropsychopharmacology.org evidence that the rapid acting antidepressant ketamine stimulates mTORC1 signaling and that this pathway is required for the behavioral actions of ketamine (Li et al, 2010, 2011).”
BackgroundInfluentialSelf-citationCohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
“The mechanisms of ketamine’s antidepressant actions are the subject of ongoing inquiry, with preclinical and clinical reports suggesting roles for increased AMPAto-NMDA receptor throughput,[39] enhanced synaptic connections in cortical and hippocampal neurons, and stimulation of brain-derived neurotrophic factor signa…”
BackgroundGABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130808 · Cited by 345
“This glutamate burst is believed to initiate activity-dependent release of brain-derived neurotrophic factor and stimulation of protein synthesis–dependent synapse formation, both of which are required for the antidepressant behavioral actions of ketamine (2, 4).”
BackgroundSelf-citationBrain-derived neurotrophic factor in mood disorders and antidepressant treatments
Castrén, E., & Kojima, M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.010 · Cited by 337
“Similar increase in BDNF mRNA and TrkB phosphorylation has been seen after acute treatment with a rapid- acting antidepressant ketamine (Li et al., 2010; Autry et al., 2011; Lepack et al., 2014; Abdallah et al., 2015; Monteggia and Zarate, 2015).”
InfluentialHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Ketamine could increase the numbers of synaptic proteins and increase the numbers and functions of new spine synapses in the rat PFC through activation of the mTORC1 signaling.(180,185) Subsequent preclinical studies have supported the role of mTORC1 signaling in the antidepressant actions of ketamine.”
BackgroundStructural and synaptic plasticity in stress-related disorders
Christoffel, D. J., Golden, S. A., & Russo, S. J. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.044 · Cited by 334
“…Ur et al. , 1992 ; de Beaurepaire , 2002 ), neurotrophic factors (Nibuya et al. , 1995 ; Chen et al. , 2001 ; Vidal et al. , 2011 ), and the ubiquitous neurotransmitter glutamate (Palucha and Pilc , 2005 ; Li et al. , 2010 ), have been shown to be crucial factors in the pathogenesis of depression.”
BackgroundFee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Self-citationOverview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329
“Spine morphogenesis and the rapid antidepressant response of ketamine is speculated to occur via enhanced AMPA receptor activity, which is induced by the increased release of presynaptic glutamate in the context of acute NMDA receptor blockade (N. Li et al., 2010).”
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression
Golden, S. A., Christoffel, D. J., Heshmati, M., Hodes, G. E., Magida, J., Davis, K., Cahill, M. E., Dias, C., Ribeiro, E., Ables, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3090 · Cited by 322
Duman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
“Initial studies demonstrated that ketamine rapidly increases synaptic number and function in the medial prefrontal cortex (mPFC) and reverses the synaptic deficits caused by chronic stress exposure (Duman, Aghajanian, Sanacora, & Krystal, 2016; Li et al., 2010, 2011).”
BackgroundSelf-citationSynaptic plasticity in depression: Molecular, cellular and functional correlates
Marsden, W. N. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.012 · Cited by 317
Kundakovic, M., & Rocks, D. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101010 · Cited by 317
“…by stress (Duman and Duman, 2015); it is important to note that this effect requires chronic treatment with traditional, slow-acting antidepressants (Hajszan et al., 2009) while ketamine induces the changes quickly in line with its fast antidepressant action (Li et al., 2010; Zhang et al., 2019).”
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.